Literature DB >> 16931911

Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch.

George N Naumov1, Lars A Akslen, Judah Folkman.   

Abstract

Tumor progression depends on sequential events, including a switch to the angiogenic phenotype (i.e., initial recruitment of blood vessels). Failure of a microscopic tumor to complete one or more early steps in this process may lead to delayed clinical manifestation of the cancer. Microscopic human cancers can remain in an asymptomatic, non-detectable, and occult state for the life of a person. Clinical and experimental evidence suggest that human tumors can persist for long periods of time as microscopic lesions that are in a state of dormancy (i.e., not expanding in tumor mass). Because it is well established that tumor growth beyond the size of 1-2 mm is angiogenesis-dependent, we hypothesized that presentation of large tumors is attributed to a switch to the angiogenic phenotype in otherwise microscopic, dormant tumors. Although clinically important, the biology of human tumor dormancy is poorly understood. The development of animal models which recapitulate the clinically observed timing and proportion of dormant tumors which switch to the angiogenic phenotype are reviewed here. The contributing molecular mechanisms involved in the angiogenic switch and different strategies for isolation of both angiogenic and non-angiogenic tumor cell populations from otherwise heterogeneous human tumor cell lines or surgical specimens are also summarized. Several imaging techniques have been utilized for the qualitative and quantitative detection of microscopic tumors in mice and their strengths and limitations are discussed. The animal models employed here permitted further studies of the angiogenic switch. These models also allowed development of an angiogenesis-based panel of blood and urine biomarkers that can be quantified and used to detect microscopic tumors before or during the angiogenic switch. If the information obtained from these animal models is translatable to the clinic, it may be possible in the future to liberate the management of cancer from a dependency on anatomical site years before it becomes symptomatic and detectable.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16931911     DOI: 10.4161/cc.5.16.3018

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  161 in total

1.  Antiangiogenic properties of an unusual benzo[k,l]xanthene lignan derived from CAPE (caffeic acid phenethyl ester).

Authors:  Giuseppina Basini; Laura Baioni; Simona Bussolati; Francesca Grasselli; Carmelo Daquino; Carmela Spatafora; Corrado Tringali
Journal:  Invest New Drugs       Date:  2010-10-06       Impact factor: 3.850

2.  Inducible gene targeting in the neonatal vasculature and analysis of retinal angiogenesis in mice.

Authors:  Mara E Pitulescu; Inga Schmidt; Rui Benedito; Ralf H Adams
Journal:  Nat Protoc       Date:  2010-08-12       Impact factor: 13.491

3.  Rapid extravasation and establishment of breast cancer micrometastases in the liver microenvironment.

Authors:  Michelle D Martin; Gert-Jan Kremers; Kurt W Short; Jonathan V Rocheleau; Lei Xu; David W Piston; Lynn M Matrisian; D Lee Gorden
Journal:  Mol Cancer Res       Date:  2010-08-19       Impact factor: 5.852

4.  Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.

Authors:  Jürgen Becker; Helena Pavlakovic; Fabian Ludewig; Fabiola Wilting; Herbert A Weich; Romulo Albuquerque; Jayakrishna Ambati; Jörg Wilting
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

5.  Modeling boundary conditions for balanced proliferation in metastatic latency.

Authors:  Donald P Taylor; Jakob Z Wells; Andrej Savol; Chakra Chennubhotla; Alan Wells
Journal:  Clin Cancer Res       Date:  2013-01-17       Impact factor: 12.531

Review 6.  Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.

Authors:  Jie Ma; David J Waxman
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

7.  Biological resonance for cancer metastasis, a new hypothesis based on comparisons between primary cancers and metastases.

Authors:  Dongwei Gao; Sha Li
Journal:  Cancer Microenviron       Date:  2013-11-10

8.  Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling.

Authors:  Rana P Singh; Komal Raina; Gagan Deep; Daniel Chan; Rajesh Agarwal
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

9.  Tumor dormancy due to failure of angiogenesis: role of the microenvironment.

Authors:  George N Naumov; Judah Folkman; Oddbjorn Straume
Journal:  Clin Exp Metastasis       Date:  2008-06-18       Impact factor: 5.150

10.  Modeling progression in radiation-induced lung adenocarcinomas.

Authors:  Hatim Fakir; Werner Hofmann; Rainer K Sachs
Journal:  Radiat Environ Biophys       Date:  2010-01-08       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.